View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
Vasopressin-receptor antagonists-vaptans for short-suppress the action of the hormone arginine vasopressin (AVP), which plays a key role in sodium and water balance. Increased AVP levels can trigger free water reabsorption in the kidneys, which may lead to increased blood volume and hyponatremia.
Vaptans are categorized into various subclasses and can be taken orally or I.V.
* Conivaptan (Vaprisol) has been FDA-approved to treat euvolemic and hypervolemic hyponatremia in hospitalized patients. Hyponatremia is the most common electrolyte imbalance in hospitalized patients. Conivaptan is contraindicated in patients with hypovolemic hyponatremia.
* Relcovaptan shows promise for treating painful menstruation, Reynaud's disease, and preterm labor.
* Mozavaptan, lixivaptan, satavaptan, and tolvaptan can remove excess water from the body without disturbing electrolyte balance, an advantage over diuretics.
* Other vaptans are being studied to treat diabetic nephropathy, cirrhosis, depression, glaucoma, Mnire's disease, cerebral vasospasm in subarachnoid hemorrhage, and small cell lung cancer.
Source: Decaux G, et al., Non-peptide arginine-vasopressin antagonists: The vaptans, The Lancet, May 10, 2008.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top